U.S. markets closed
  • S&P Futures

    4,250.50
    +4.75 (+0.11%)
     
  • Dow Futures

    34,495.00
    +33.00 (+0.10%)
     
  • Nasdaq Futures

    14,023.75
    +29.50 (+0.21%)
     
  • Russell 2000 Futures

    2,332.50
    +2.00 (+0.09%)
     
  • Crude Oil

    71.24
    +0.33 (+0.47%)
     
  • Gold

    1,866.60
    -13.00 (-0.69%)
     
  • Silver

    27.91
    -0.24 (-0.84%)
     
  • EUR/USD

    1.2104
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    1.4620
    +0.0030 (+0.21%)
     
  • Vix

    15.65
    -0.45 (-2.80%)
     
  • GBP/USD

    1.4113
    -0.0004 (-0.03%)
     
  • USD/JPY

    109.7420
    +0.1070 (+0.10%)
     
  • BTC-USD

    38,985.23
    +3,422.48 (+9.62%)
     
  • CMC Crypto 200

    976.29
    +34.48 (+3.66%)
     
  • FTSE 100

    7,134.06
    +45.88 (+0.65%)
     
  • Nikkei 225

    29,109.52
    +160.79 (+0.56%)
     

Cerecor Inks New Global License Agreement With Kyowa Kirin For CERC-002

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Cerecor Inc's (NASDAQ: CERC) wholly-owned subsidiary, Aevi Genomic Medicine LLC, has entered into an expanded agreement with Kyowa Kirin Co Ltd (OTCMKTS: KYKOF) for exclusive worldwide rights to CERC-002 for all indications, including severe pediatric-onset inflammatory bowel disease and ARDS (including COVID-19 ARDS).

  • Under the terms of the agreement, Cerecor will receive exclusive rights for the development, manufacturing, and commercialization of the antibody for all indications worldwide, including the U.S., Europe, and Japan.

  • Kyowa Kirin can retain the rights in Japan and receive an up-front payment from Cerecor. It is also eligible to receive additional milestone payments and sales-based royalties, and a share of sublicensing income.

  • CERC-002 is a fully human anti-LIGHT or tumor necrosis factor superfamily member 14 (TNFSF14) monoclonal antibody licensed from Kyowa Kirin.

  • Price Action: CERC shares are trading 2.68% at $3.06 in premarket on the last check Monday.

See also: Best Life Insurance for Children 

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.